Schedule at a Glance
|
|||
Friday, July 12 |
|||
1-5 p.m. |
Registration open |
||
Saturday, July 13 |
|||
7:30 a.m.–5 p.m |
Registration open |
||
8 a.m.-3:45 p.m. |
|||
8 a.m.-4:15 p.m. |
|||
8:30 a.m.–5 p.m. |
|||
8:30 a.m.–5 p.m. |
|||
Sunday, July 14 |
|||
7 a.m.–5:15 p.m. |
Registration open |
||
8:30 a.m.–10 a.m |
Symposia and Featured Research Sessions | ||
|
S1-01 Lipid Metabolism | ||
|
S1-01-01 | ApoE and apoE Receptors in Brain Lipid Metabolism, Synaptic Functions and Clearance of Amyloid-beta | |
|
S1-01-02 | Lipid Metabolism in the Brain and Neurodegeneration | |
|
S1-01-03 | Are Metabolic Risk Factors also Risk Factors Alzheimer’s Disease or Vascular Dementia? | |
|
S1-01-04 | Cholesterol Metabolites as Endogenous Gamma Secretase Modulators | |
|
S1-02 Mild Cognitive Impairment Associated with Non-Amyloid Biomarker Findings | ||
|
S1-02-01 | Epidemiology of Mild Cognitive Impairment: The Mayo Clinic Study of Aging | |
|
S1-02-02 | Clinical/Neuropsychological Features | |
|
S1-02-03 | Neuroimaging | |
|
S1-02-04 | Neurodegenerative Predictors of Decline in MCI: Relationship to Amyloid Status | |
10 a.m.–4 p.m. |
Exhibit Hall open |
||
10 a.m.–10:45 a.m. |
Morning break |
||
10:45–11:45 a.m. |
General Session |
||
PL-01-01 | Amyloid PET Imaging in Clinical Practice | ||
11:45 a.m.–2:15 p.m. |
Poster Sessions |
||
|
Lunch on your own |
||
2:15–3:45 p.m. |
Oral Sessions |
||
4–5:30 p.m. |
Oral Sessions |
||
5:30–7:30 p.m. |
Welcome Reception |
||
|
|||
Monday, July 15 |
|||
7:30 a.m.–5:15 p.m. |
Registration open |
||
8:30–10 a.m. |
Symposia and Featured Research Sessions |
||
|
S2-01 Non-Cognitive Aspects of Health and Well-Being in Dementia | ||
|
S2-01-01 | Physical Morbidity in Dementia | |
|
S2-01-02 | Deaf with Dementia | |
|
S2-01-03 | Delirium | |
|
S2-01-04 | Avoiding Unnecessary Hospital Admissions from Residential Care for Ambulatory Care Sensitive Conditions | |
|
S2-02 Lewy Body Spectrum Disorders | ||
|
S2-02-01 | Prodromal Features of DLB/PDD | |
|
S2-02-02 | Clinical and Neuropsychological Features as Predictors from MCI to AD-Type Dementia | |
|
S2-02-03 | Cerebrospinal Fluid (CSF) Biomarker | |
|
S2-02-04 | Neuroimaging | |
10 a.m–4 p.m. |
Exhibit Hall open |
||
10–10:45 a.m. |
Morning break |
||
10:45–11:45 a.m. |
General Session |
||
|
PL-02-01 | Policy, Systems and Care | |
|
PL-02-02 | Tau Therapeutics | |
11:45–2:15 p.m. |
Poster Sessions |
||
2:15–3:45 p.m. |
Oral Sessions |
||
4–5:30 p.m. |
Oral Sessions |
||
|
|||
6-7 a.m. |
AAIC 5K Run/Walk |
||
7:30 a.m–5:15 p.m. |
Registration open |
||
8:30–10 a.m. |
Symposia and Featured Research Sessions |
||
|
S3-01 Life-Course Approach and Temporal Trends in Dementia Incidence | ||
|
S3-01-01 | Dynamic Processes in Life-Course: Exposure to Risk and Incidence of Dementia CFAS-II | |
|
S3-01-02 | Temporal Trends and Methodological Issues: Is Dementia Incidence Declining? SNACK Study | |
|
S3-01-03 | Risk Factors for Dementia in Life Course Approach | |
|
S3-01-04 | Changes in Dementia Risk Factors Over 40 Years: Experiences from Finland | |
|
S3-02 Proteostasis | ||
|
S3-02-01 | Proteostasis Networks | |
|
S3-02-02 | Autophagy and Neurodegeneration | |
|
S3-02-03 | Regulation of Protein Quality Control: Implications for Neurodegeneration | |
|
S3-02-04 | Researcher selected from submitted abstracts | |
10 a.m–4 p.m. |
Exhibit Hall open |
||
10–10:45 a.m. |
Morning break |
||
10:45–11:45 a.m. |
General Session |
||
|
PL-03-01 | Public Health and Epidemiology | |
|
PL-03-02 | Synaptic Biology of AD: From Basic Mechanism to Novel Treatments | |
11:45 a.m.–2:15 p.m. |
Poster Sessions |
||
2:15–3:45 p.m. |
Oral Sessions |
||
4–5:30 p.m. |
Oral Sessions |
||
Wednesday, July 17 |
|||
7:30 a.m.–5:15 p.m. |
Registration open |
||
8 a.m.-5 p.m. |
|||
8:30–10 a.m. |
Symposia and Featured Research Sessions |
||
|
S4-01 Seeding and Spreading of Proteinopathies | ||
|
S4-01-01 | Seeded Initiation and Spread of Aggregated Aß | |
|
S4-01-02 | Tau | |
|
S4-01-03 | Synuclein | |
|
S4-01-04 | PrP | |
|
S4-02 Beyond Amyloid: From Basic Biology to Therapeutics | ||
|
S4-02-01 | Abnormal Hyperphosphorylation of Tau and Molecular Mechanism of Neurofibrillary Degeneration | |
|
S4-02-02 | Tau Immuno-Therapy – How to Crack the Immune Code of Misfolded Protein Tau | |
|
S4-02-03 | Treating Alzheimer’s Disease With an O-GlcNAcase Inhibitor | |
|
S4-02-04 | Targeting Alzheimer's Related Mechanisms with p75 Ligands | |
10 a.m.–4 p.m. |
Exhibit Hall open |
||
10–10:45 a.m. |
Morning break |
||
10:45–11:45 a.m. |
General Session |
||
|
PL-04-01 | Targeting Beta-Secretase | |
|
PL-04-02 | Developing Topics Plenary Speaker | |
11:45–2:15 p.m. |
Poster Sessions |
||
2:15–3:45 p.m. |
Oral Sessions |
||
4–5:30 p.m. |
Oral Sessions |
||
6:30-8:30 p.m. |
|||
Thursday, July 18 |
|||
8:30–10 a.m. |
Symposia and Featured Research Sessions |
||
10–10:15 a.m. |
Morning break |
||
10:15–11:15 a.m. |
General Session |
||
|
PL-05-01 | Are our Animal Models of Alzheimer’s Disease Good Enough? | |
|
PL-05-02 | The Utility of Fluid Biomarkers in Research, Trial Design and Clinical Practice | |
11:30 a.m.–1 p.m. |
Oral Sessions |
||
Spotlight
Registration and housing are now open! Join us to celebrate 25 years of discovery, progress and change at AAIC in Boston, United States, July 13-18, 2013.
Register now.
